About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Markers for Chronic Obstructive Pulmonary Disease (COPD)

Markers for Chronic Obstructive Pulmonary Disease (COPD)

NCT00180622·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Imperial College London

With

AstraZeneca

Age

30–75

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Healthy non-smokers
FEV1 \>80% predicted
FEV1 reversibility of \<10% after inhaled (beta2-agonists
Current smokers
FEV1 no less than 80% predicted
FEV1 reversibility of \<10% after inhaled (beta2-agonists
Smoking history of \> 10 pack-years
Moderate COPD
FEV1 40-59% predicted
FEV1 reversibility of \<10% after inhaled (beta2-agonists
Smoking history of \> 10 pack-years\*\*
Severe COPD
FEV1 \<40% predicted
FEV1 reversibility of \<10% after inhaled (beta2-agonists
Smoking history of \> 10 pack-years

You may not be if

FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists
Asthma
unstable disease (FEV1 \<35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.

The record

StatusWithdrawn

PhaseNo phase

Taking part0

StartedJul 2001

UpdatedJul 5, 2019

Conditions

Healthy Non-smokers Current Smokers COPD Patients

Where1

Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom